文献速递肝病消化道肿瘤与早癌

非酒精性脂肪性肝病伴肝酶水平升高对肝硬化和肝细胞癌风险的影响

Influence of Nonalcoholic Fatty Liver Disease With Increased Liver Enzyme Levels on the Risk of Cirrhosis and Hepatocellular Carcinoma.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-02-04

研究纳入129,374名30岁及以上、乙型肝炎表面抗原和丙型肝炎病毒抗体阴性且每日饮酒有限的健康筛查参与者,按腹部超声分为非酒精性脂肪性肝病伴肝酶升高组、伴肝酶正常组及无该病且肝酶正常组。经全国登记数据联动确定肝硬化和肝细胞癌发病率,Cox比例风险模型显示伴肝酶升高组肝硬化和肝细胞癌风险显著升高,而伴肝酶正常组无显著差异;结论认为伴肝酶升高者风险显著更高,应进行监测。

要点

  • 非酒精性脂肪性肝病伴肝酶升高组肝硬化和肝细胞癌风险显著高于无该病且肝酶正常组。
  • 非酒精性脂肪性肝病伴肝酶正常组肝硬化和肝细胞癌风险与无该病且肝酶正常组无显著差异。
  • 伴肝酶升高者应进行监测。

核心结论

  • 非酒精性脂肪性肝病伴肝酶水平升高者肝硬化和肝细胞癌风险显著更高,应进行监测。

研究设计与样本

  • 研究纳入129,374名30岁及以上成人,均于2008年至2013年参加健康筛查,乙型肝炎表面抗原和丙型肝炎病毒抗体阴性,且每日饮酒量有限(男性<20 g/d,女性<10 g/d)。
  • 采用腹部超声确定非酒精性脂肪性肝病,参与者分为非酒精性脂肪性肝病伴肝酶升高组、伴肝酶正常组和无该病且肝酶正常组。
  • 通过计算机数据联动全国登记系统确定肝硬化和肝细胞癌发病率,采用Cox比例风险模型估计风险比。

主要发现

  • 肝硬化和肝细胞癌发病率按以下顺序升高:无该病且肝酶正常组(n=66,801;51%)、非酒精性脂肪性肝病伴肝酶正常组(n=41,461;32%)、伴肝酶升高组(n=21,112;16%)。
  • 与非酒精性脂肪性肝病无该病且肝酶正常组相比,伴肝酶升高组和伴肝酶正常组的肝硬化的多变量校正风险比分别为3.51(95%CI:2.36-5.22)和0.73(95%CI:0.46-1.16),肝细胞癌风险比分别为1.91(95%CI:1.08-3.38)和0.57(95%CI:0.31-1.04)(趋势P<.001)。
  • 将分析限制于非肥胖个体(体重指数<25 kg/m2)及非肥胖且无糖尿病个体后,结果一致(P<.05)。

临床怎么用

  • 作者认为非酒精性脂肪性肝病伴肝酶水平升高者肝硬化和肝细胞癌风险显著更高,应进行监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The influence of nonalcoholic fatty liver disease (NAFLD) on the long-term risk of cirrhosis and hepatocellular carcinoma (HCC) in Asian populations has not been widely investigated. METHODS: We enrolled 129,374 adults aged 30 years and older, all of whom participated in a health screening program from 2008 through 2013, were seronegative for hepatitis B surface antigen and anti-hepatitis C virus antibodies, and had limited daily alcohol consumption (<20 g/d for men and <10 g/d for women). Abdominal ultrasonography was performed to determine the presence of NAFLD. The participants were divided into the following groups: NAFLD with increased or normal liver enzyme levels, and non-NAFLD with normal liver enzyme levels. The incidences of cirrhosis and HCC were determined through computerized data linkage with nationwide registries. Cox proportional hazard models were used to estimate the hazard ratios of NAFLD on the risks of cirrhosis and HCC. RESULTS: The incidence rates of cirrhosis and HCC increased as follows: non-NAFLD with normal liver enzyme levels (n = 66,801; 51%), NAFLD with normal liver enzyme levels (n = 41,461; 32%), and NAFLD with increased liver enzyme levels (n = 21,112; 16%). In the NAFLD group with increased liver enzyme levels and the NAFLD group with normal liver enzyme levels, the corresponding multivariate-adjusted hazard ratios for cirrhosis were 3.51 (95% confidence interval [CI]: 2.36-5.22) and 0.73 (95% CI: 0.46-1.16), and for HCC were 1.91 (95% CI: 1.08-3.38) and 0.57 (95% CI: 0.31-1.04), respectively, compared with the non-NAFLD group (P for trend < .001). The findings were consistent after restricting the analysis to nonobese individuals (body mass index, <25 kg/m2) and nonobese individuals without diabetes (P < .05). CONCLUSIONS: Individuals with NAFLD and increased liver enzyme levels showed significantly higher risks for cirrhosis and HCC and should be monitored.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Huang YH, Chan C, Lee HW, et al. Influence of Nonalcoholic Fatty Liver Disease With Increased Liver Enzyme Levels on the Risk of Cirrhosis and Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2022. PMID: 35124270. doi:10.1016/j.cgh.2022.01.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。